drugset
drugset / Trial / NCT02708173

Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older

NCT02708173 ↗

Phase 1 Completed 40 enrolled Beijing Chaoyang District Centre for Disease Control and Prevention
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study evaluates the safety of Quadrivalent Influenza Virus Vaccine in Healthy People Aged years 3 to 60.40 Subjects will be equally divided into 2 groups,including 3-17 years old and 18-60 years old.Adult group first receive one dose of Quadrivalent Influenza Virus Vaccine.Then minors group also receive one dose of Quadrivalent Influenza Virus Vaccine after 7 days.

Timeline

Start
2016-03
Primary completion
2016-03
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Quadrivalent Influenza Virus Vaccine Vaccine — —

Indications

No indication recorded.